Hunger pain: semaglutide in schizophrenia

Eleven people with schizophrenia sat down with a Danish research team and described what hunger felt like on antipsychotic medication, and what changed once they started semaglutide for weight management alongside their psychiatric treatment. The interviews, published in the International Journal of Qualitative Studies on Health and Well-being on 18 August 2026, gave a name to something several participants had struggled to put into words before. The authors call it hunger pain^[1]: an excruciating combination of feeling extremely hungry, never achieving satiety, and relentless preoccupation with thoughts about food.

How the interviews were done

The study sits inside a larger trial called HISTORI, short for Home-based Intervention with Semaglutide Treatment of Neuroleptic-Related Prediabetes. For this qualitative sub-study, the team interviewed six women and five men. The interviews happened between four months and one and a half years after each participant finished a course of semaglutide^[1]. Using semi-structured interviews and thematic analysis, the researchers grouped what they heard into three themes. First came hunger pain caused by antipsychotic medicine. Next was the mix of relief and drawbacks that came with reduced hunger on semaglutide. The third theme looked at the everyday habits that shape how someone eats.

Why antipsychotics make hunger different

Weight gain is one of the best-documented side effects of many antipsychotic drugs, particularly the newer, second-generation agents used widely in schizophrenia care. Some of that effect runs through appetite centers in the brain, the same general area that semaglutide acts on from the other direction. Semaglutide is a GLP-1 analogue: it binds the receptor for a gut hormone that tells the brain a meal is finished, and part of its effect on weight comes from making people feel full sooner and longer. What this new interview study adds is language for the subjective experience behind antipsychotic-driven weight gain. Participants did not describe ordinary hunger. They described something closer to physical pain: a hunger that never resolved into fullness and that kept pulling their attention back to food. The authors write that antipsychotic medicine likely triggered this hunger pain, and that hunger pain in turn reinforced unhelpful coping habits around eating^[1].

What changed after semaglutide, and what did not

Most participants described real relief. The preoccupation eased, meals felt satisfying in a way they had not for a long time, and several said they felt back in control of their own eating^[1]. But the picture was not uniformly positive. Some participants also described downsides to having their appetite suppressed this strongly, and the research team recommends that clinicians assess a patient's eating difficulties before starting semaglutide, not only after^[1]. That recommendation matters because appetite and eating are already complicated territory for many people living with schizophrenia, and a drug that changes hunger this much can affect more than body weight.

Where semaglutide's evidence in this population stands

Semaglutide is a GLP-1 receptor agonist sold for type-2 diabetes and, at higher doses, for chronic weight management. It is not approved to treat any psychiatric condition. Interest in the wider GLP-1 drug class for antipsychotic-induced weight gain has been building for a few years. A 2024 systematic review and meta-analysis pooled five randomized trials and one cohort study of two older GLP-1 drugs, exenatide and liraglutide, in people taking antipsychotics, and found meaningful weight loss without a worsening of psychiatric symptoms^[2]. In that review, liraglutide produced a mean weight loss of 4.70 kilograms against comparison groups, while exenatide's result was smaller and did not reach statistical significance^[2]. The most common adverse events in that review were gastrointestinal: nausea, vomiting, and diarrhea, and the reviewers reported that neither drug worsened psychiatric symptoms^[2]. Semaglutide itself was not part of that pooled analysis. That is part of why this new interview study matters. It is an early look at how people in this population actually experience semaglutide, ahead of the larger controlled trials still needed to establish its safety and effectiveness here.

What this study does not show

Eleven interviews is a small sample, and this was a qualitative sub-study built to describe experience, not to measure safety or efficacy. It does not tell us how semaglutide performs against a placebo in this population, and it does not establish that the drug is appropriate for everyone with a psychiatric diagnosis. Semaglutide remains a prescription-only medicine everywhere PeptideMethods covers regulation, authorized as an adjunct to diet and exercise rather than as a standalone intervention^[3]. Starting, stopping, or combining it with antipsychotic treatment is a decision for the treating psychiatrist and prescriber, not something this research supports doing alone.

Talk to the prescribing team before anything changes

If this description matches your own experience or a family member's, it is worth raising directly with the psychiatrist or GP managing the antipsychotic prescription. The researchers built a case for taking that experience seriously and for screening eating difficulties before treatment starts. They did not build a case for adjusting medication without medical supervision, and neither do we. Our semaglutide page has the fuller regulatory and safety picture for anyone weighing this conversation with their care team.